# Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

> **NCT02115243** · PHASE1 · COMPLETED · sponsor: **Duke University** · enrollment: 4 (actual)

## Conditions studied

- Unresectable Melanoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02115243
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-12-07
- **Final completion:** 2015-12-07
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115243, "Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02115243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*